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1. production 
In recent years it has been shown that the group 
of diseases known as phenylketonuria ncludes very 
rare and severe diseases caused by defects in biopterin 
metabolism [l-6]. These findings have focused inter- 
est on a new area of research that may also have great 
significance for neuroscience and future treatment of 
affective disorders. Tetrahydrobiopte~n (BH,) is a 
cofactor of the monooxygenases phenylalanine-4- 
hydroxylase, tyrosine-3-hydroxylase and probably 
also tryptoph~-S-hydroxyla~, key enzymes in 
dopamine and serotonin production. Biopterin is 
formed from guanosine triphosphate in several steps, 
some of which are not known exactly. We report here 
the detection of 3’-hydroxysepiapterin (HS) in urine 
from a patient with defective dihydrobiopterin (BH,) 
biosynthesis. This finding could be of value for the 
understanding of biopterin biosynthesis and the more 
exact localization of the enzyme defect in biopterin- 
deficient patients. 
2. Materials and methods 
2.1. Patients with d~hydrobj~p~e~~ deficiency 
Z. Y., female, born in September 1976: Case 
report in [7]. B. E., female, born 3 May 1979. A 
detailed case report will be published in [8]. In both 
patients, the metabolic defect lies between dihydro- 
neopterin triphosphate and L-sepiapterin [S&j. Z. Y. 
and B. E. need BH4 dihydrochloride in daily doses of 
1.25 and 2.5 mg/kg, respectively, to keep their plasma 
phenylalan~e l vels normal when on a diet unre- 
stricted in protein. 
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Urine portions were stored frozen without any 
additives. Samples were protected from direct light, 
Pterin-6carboxylic acid (P6C) was from Fluka AG 
(Buchs SG); other pterins except for HS, were 
obtained from Professor M. Viscontini, University of 
Zurich, and Dr B. Schircks, CH-8623 Wetzikon. 
2.3.3’-Hydroxysep~p terin (6(I f-~~~-2r,31- 
dihydroxypropylj 7,8_dihydropterin (HS) 
This was prepared analogously to L-sepiapterin (S) 
[9] as follows. Tetrahydroneopterin dihydrochloride, 
12 mg (36 ymol) in 2 ml 0.15 mol/l sodium acetate 
(pH 4.1) was kept for 5 days in an open 25 ml round- 
bottom flask in the dark. After evaporation to dry- 
ness, the residue was redissolved in water at 60°C 
and chromatographed ona 1.6 X 28 cm column of 
cellulose in water at a 50 ml/h flowrate. The main 
yellow zone eluted between 105-150 ml and was 
re~hromato~aphed on a 1.6 X 25 cm column of 
Sephadex G-15 in water. The eluate between 
76- 106 ml was evaporated to dryness, the residue 
dissolved in warm absolute thanol and precipitated 
with die~ylether to give chromatograp~c~ly pure 
HS. The yield was -2 mg. 
2.4 I~l~~io~ of the unknown compound from urine 
of patient 3. E. 
Urine, 50 ml, creatinine cont. 18 mg/dl, was con- 
centrated to -10 ml in vacua, centrifuged and the 
clear supernatant chromatographed on a 1.6 X 28 cm 
column of Sephadex G- 1 S in water. The eluate 
between 80-l 10 ml was collected. Two further 50 ml 
urine portions were treated similarly and the corre- 
sponding yellow fractions combined for rechromatog- 
raphy on a 1.6 X 25 cm column of cellulose in water. 
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The eluate between 125-158 ml was collected, con- 
centrated in vacua and stored frozen. 
2.5. Derivatives 
Methoxime derivatives were prepared in absolute 
pyridine at 60°C for 3 h, using methoxyamine hydro- 
chloride, 2% in pyridine. Trimethylsilyl derivatives 
were prepared in bistrimethylsilyl-trifluoroacetamide 
(1: 1, v/v) for 1 h at 1OO’C. Reduction/oxidation of 
aqueous HS or S, respectively, was performed with 
NaBHa for 1 min followed by adjustment to pH 2 
with HCl, shaking with MnOz for 5 min and centri- 
fugation. 
2.5. High-performance liquid chromatography 
(HPLC) 
Samples were filtered through SEP-PAK Cis car- 
tridges (Waters Assoc., Milford, MA) using 20 ml 
water. HPLC was performed on a 4.5 X 250 mm col- 
umn of 7 pm Lichrosorb RP-8 (Knauer, Berlin) using 
acetic acid-water (1:2000, v/v) as solvent at 44’C 
and fluorimetric detection at 350/450 nm (oxidized, 
blue fluorescing pterins) or 420/530 nm (HS, S). Gas 
chromatography-mass pectrometry (GC-MS) was 
performed on a 20 m SE-52 glass capillary column 
(H. Jaeggi, Trogen) at 175-25O”C, 6’C/min, He 1 bar 
with direct coupling to a mass spectrometer (F-16, 
Vacuum Generators, Altrincham) and an INCOS data 
system (Finnigan Instr., Sunnyvale, CA). All spectra 
were taken at 20 eV. High-voltage electrophoresis 
(HEP) was performed at 100 V/cm in acetic acid- 
formic acid-water (120:26:850, v/v/v) pH 1.9 on 
Schleicher and Schiill paper no. 2043 B. 
3. Results 
In urine of patients Z. Y. and B. E., a yellow 
fluorescing spot was visible on paper high-voltage 
electrophoresis (HEP) with a low mobility very simi- 
lar to S at pH 1.9, but with a lower migration rate 
than S in paper chromatography in water or in 
1 -butanol-acetic acid-water solvents. The isolated 
yellow compound showed a UV spectrum &t 216, 
268 and 424 nm with log E 4.21,4.22 and 4.02, 
respectively) and fluorescence spectrum (z,” 420/ 
530 nm) similar to S. It gave threo- and erythro- 
neopterin (Ne) in a ratio of 2.0: 1 after reduction/ 
oxidation as did synthetic HS; whereas S gave a 
threo-/erythro-biopterin ratio of 1.34: 1 under the 
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same conditions, measured by HPLC and checked by 
MS. The isolated compound could be degraded to 
pterin-6carboxylic (P6C) acid by treatment with 
KMn04 or MnO,. The isolated compound could 
not be distinguished chromatographically from syn- 
thetic HS, neither as the free compounds nor as the 
methoxime-7,8-dehydro derivatives in HEP at pH 1.9 
and 100 V/cm, the relative mobilities (uncorrected 
for electroendosmosis) of HS, 7,8dehydro-HS- 
methoxime, S, 7,8-dehydroS-methoxime, B, Ne, 
P6C and Xanthopterin (X) were 12,52, 16,62, 100, 
96,21 and 50, respectively. In paper chromatography 
in l-butanol-acetic acid-water (20:3:7, v/v/v), the 
RF X 100 values of these compounds were 19,37, 
33,55,20,33,20 and 31, respectively. HS, Ne, B, X 
eluted in HPLC on RI-8 at 44’C after 10.8,4.89, 
8.94 and 6.30 min, respectively. The number of tri- 
methylsilyl (TMS) groups of the derivatives of HS, 
7,8-dehydro-HS-methoxime, B and X were 5,4,4 
and 3, and these compounds eluted in GC on a SE-52 
glass capillary after 590,607,427 and 249 s, respec- 
tively. 
The isolated compound gave an electron impact 
(20 eV) mass spectrum identical to that of authentic 
HS (TMS)senol with signals at m/e (% rel. intensity) 
613 (M’, loo), 598 (12) 541 (4), 523 (9) 510 (6) 
495 (3), 449 (3), 409 (3) 408 (3) 381 (8) 380 (7) 
307 (2) 205 (2) 147 (5). Isolated and synthetic 
compounds gave a small additional GC peak of HS 
(TMS)6 eluting at 620 s. More structural information 
was given by the electron impact (20 eV) mass spec- 
tra of the methoxime derivatives. 
7,8-Dehydro-HS-methoxime (TMS)4 showed main 
signals at m/e 568 (M’, 23%) 553 (17) 537 (28) 
478 (69) 465 (6) 447 (42) 332 (37) 317 (52) 
204 (100) 189 (30) 147 (33), 133 (29), 117 (50). 
The ion at m/e 204 (base signal) is interpreted as 
TMS-0-CH = CH-OTMS resulting from side chain 
cleavage, which also leads to CHaOH and 6-cyano- 
pterin (TMS)2, the latter giving strong signals at m/e 
332 and 3 17. An analogous fragmentation pattern 
was observed in MS of 7,8dehydrosepiapterin 
methoxime (TMS)a. 
Using synthetic HS as standard, several urine spec- 
imens were analyzed by HPLC at 420/530 nm after 
prepurification on Sep-Pak Cr,.,. When concentration 
was expressed in mmol/mol creatinine, values of 3.9, 
9.65,5.64,5,54 and 7.54 were found in urine speci- 
mens of patient B. E., B. E., B. E., Z. Y., and Z. Y., 
respectively, and 0.17,0.07 and 0.02 in 3 urines from 
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healthy controls. Only traces of HS were found in 
urine of patients with dihydropteridine reductase 
deficiency. 
4. Discussion 
From these results we conclude that the isolated 
compound is HS. It is present in fresh, native urine, 
as was shown by HEP. HS has been described in [IO] 
as one of the products formed during reoxidation of 
dihydroneopterin by air. We found that HS is formed 
in high yield from NeH4 at pH 4 under the same con- 
ditions as S is formed from BH4 [9]. 
The origin of urinary HS is not yet known; three 
possible ways of formation are shown in scheme 1. 
It may arise at least partially from dihydroneopterin 
by enzymic or nonenzymic oxidation, even during 
the standing of urine before analysis. Then, one 
would also expect elevated urinary S when BH? is 
elevated, as in patients with dihydropteridine reduc- 
tase deficiency. However, we could never observe 
this. At room temperature, HS was formed only 
slowly from NeH4 added to normal human urine. 
Furthermore, a urine portion from patient B. E., col- 
lected directly on dry ice and kept deep frozen until 
just before analysis, contained 3.9 mmol HS/mol 
creatinine. 
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This may indicate that HS is of endogenous origin 
and is a normal metabolite in man. One might even 
speculate that urinary dihydroneopterin could origi- 
nate from HS by enzymic reduction. As shown in 
scheme 1, HS could arise from dihydroneopterin tri- 
phosphate (NeH2P,), a well known intermediate in 
biopterin biosynthesis [l l-131. NeH2Ps was claimed 
to be converted in rat brain into dihydrobiopterin 
(BH,) by a single enzyme, called BHTsynthetase 
[ 141. However, in kidneys of Syrian golden hamster 
[ 151 and chicken [IS], at least 2 enzymes were 
necessary for this reaction. Under certain conditions, 
S was a free intermediate [13,15,16]. In [13] A 
chicken kidney enzyme preparation ‘A*’ was obtained 
which transformed NeH*Ps into an unknown inter- 
mediate (Shiota’s X) with a postulated structure of 
6-(l’-2’-dioxopropyl)-7,8-dihydropterin. The triphos- 
phate of HS would fit into this postulated pathway 
(scheme 1) as the precursor of the dioxo-compound 
(by elemination of inorganic Pa for BH2 biosynthesis) 
and of HS (by hydrolysis of the triphosphate ester, 
‘overflow pathway’). The observed accumulation of 
urinary HS in patients with BHTdeficiency could 
mean that they are unable to eliminate the triphos- 
phate group in the normal way. Instead, the overflow 
pathway of hydrolysis by a (tri)phosphatase may 
occur. A third possible but less likely pathway leading 
to HS would be hydration of ‘Shiota’s X’ (scheme 1). 
Scheme 1 
postulated steps in dihydrobiopterin biosynthesis and possible pathways for formation of 3’-hydroxysepiapterin 
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Increased urinary HS in addition to elevated Ne 
may be used for diagnosis of a defect in BH2 biosyn- 
thesis. Analysis by HPLC with fluorimetric detec- 
tion at 420/530 nm is very simple and highly specific. 
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